← All candidates
6 insider filings on record.
6 filings on record.
LEXXLexaria Bioscience Corp.
—
$0.6201
-3.58% · Sep 16
6 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Bunka Christopher
Bought $14.4K on Jul 29 — 15,600 sh @ $0.9215, held indirect, 5.8% of their stake.
First Form 4 on file
Chief Executive Officer
Christopher Richard
Bought $13.6K on Jul 29 — 15,000 sh @ $0.9094, held direct, 23% of their stake.
First Form 4 on file
President & CSO
Docherty John Martin
Bought $5.0K on Jul 29 — 5,376 sh @ $0.9280, held direct, 100% of their stake.
First Form 4 on file
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
1 more transaction on Pro →Context
Wall St
$52.50 avg target
+8366.4% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
The file stays open
6 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice